Skip to main content
SpringerLink
Log in

Prevent and treat the clinical sequelae of sickle cell disease in children with care

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The current therapeutic strategies for paediatric sickle cell disease focus on preventing and treating the clinical manifestations of this genetic condition. The mainstays of disease-modifying therapy include antibacterial prophylaxis, hydroxycarbamide (hydroxyurea) and monthly blood transfusion. The only currently available cure is haematopoietic stem cell transplant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Sci World J. 2008;8:1295–342.

    Article  Google Scholar 

  2. Meier ER, Miller JL. Sickle cell disease in children. Drugs. 012;72(7):895–906.

  3. Vichinsky E, Lubin BH. Suggested guidelines for the treatment of children with sickle cell anemia. Hematol Oncol Clin North Am. 1987;1(3):483–501.

    PubMed  CAS  Google Scholar 

  4. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr. 1995;127(5):685–90.

    Article  PubMed  CAS  Google Scholar 

  5. Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a Working Party of the Haemato-Oncology Task Force. Br J Haematol. 2011;155(3):308–17.

    Article  PubMed  CAS  Google Scholar 

  6. Ahmad FA, Macias CG, Allen JY. The use of incentive spirometry in pediatric patients with sickle cell disease to reduce the incidence of acute chest syndrome. J Pediatr Hematol Oncol. 2011;33(6):415–20.

    Article  PubMed  Google Scholar 

  7. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333(4):206–13.

    Article  PubMed  CAS  Google Scholar 

  8. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.

    Article  PubMed  CAS  Google Scholar 

  9. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary (no. 64). Sep 2012.

  10. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–72.

    Article  PubMed  CAS  Google Scholar 

  11. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–91.

    Article  PubMed  CAS  Google Scholar 

  12. Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550–4.

    PubMed  CAS  Google Scholar 

  13. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137(5):479–85.

    Article  PubMed  Google Scholar 

  14. Shenoy S. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant. 2007;40(9):813–21.

    Article  PubMed  CAS  Google Scholar 

  15. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309–17.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

This article was adapted from Drugs 2012;72(7):895–906 [2]. The preparation of this article was not supported by any external funding; the original review [2] was supported by the US National Institute of Diabetes and Digestive and Kidney Diseases.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Prevent and treat the clinical sequelae of sickle cell disease in children with care. Drugs Ther Perspect 29, 200–204 (2013). https://doi.org/10.1007/s40267-013-0040-1

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0040-1

    Keywords

    Search

    Navigation